Literature DB >> 18757243

Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.

Giorgos Bamias1, Spyros I Siakavellas, Kimon S Stamatelopoulos, Elda Chryssochoou, Christos Papamichael, Petros P Sfikakis.   

Abstract

TL1A is a novel TNF-like cytokine, which provides co-stimulatory and Th1-polarizing signals to activated lymphocytes, via binding to death-domain receptor 3 (DR3). These functions are inhibited when TL1A associates to decoy receptor 3 (DcR3). We investigated the serum expression of TL1A and DcR3 in 81 patients with RA and 51 healthy controls. TL1A concentrations were elevated in patients by 5-fold (P<0.00001). This increase was more prominent in RFactor-positive patients and correlated with clinical activity in this subgroup. DcR3 was detected more frequently and in significantly higher values in RA-derived sera, correlated strongly with TL1A, and was present in inflammatory synovial fluid. Severe RA stage was associated with highly elevated TL1A and DcR3 serum levels. Treatment with an anti-TNF agent significantly decreased TL1A serum levels. We conclude that TL1A may serve as an inflammatory marker in RA. Interactions between TL1A and its receptors may be important in the pathogenesis of RA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757243     DOI: 10.1016/j.clim.2008.07.014

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  38 in total

1.  On death receptor 3 and its ligands….

Authors:  Eddie C Y Wang
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

Review 2.  TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation.

Authors:  Françoise Meylan; Arianne C Richard; Richard M Siegel
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

3.  The expression of death decoy receptor 3 was increased in the patients with primary Sjögren's syndrome.

Authors:  Jinlin Liu; Zhao Zhao; Yuqiong Zou; Mei Zhang; Yonglie Zhou; Yasong Li; Zhenzhen Pang; Weidong Jin
Journal:  Clin Rheumatol       Date:  2015-01-08       Impact factor: 2.980

4.  Polymorphic variants of LIGHT (TNF superfamily-14) alter receptor avidity and bioavailability.

Authors:  Timothy C Cheung; Ken Coppieters; Hideki Sanjo; Lisa M Oborne; Paula S Norris; Amy Coddington; Steven W Granger; Dirk Elewaut; Carl F Ware
Journal:  J Immunol       Date:  2010-06-30       Impact factor: 5.422

5.  TL1A regulates adipose-resident innate lymphoid immune responses and enables diet-induced obesity in mice.

Authors:  Peter Tougaard; Louise Otterstrøm Martinsen; Ditte Olsen Lützhøft; Henrik Elvang Jensen; Mette Flethøj; Peter Vandenabeele; Anders Elm Pedersen; Søren Skov; Axel Kornerup Hansen; Camilla Hartmann Friis Hansen
Journal:  Int J Obes (Lond)       Date:  2020-01-30       Impact factor: 5.095

Review 6.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.

Authors:  Michael Croft; Richard M Siegel
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

7.  Human primary biliary cirrhosis-susceptible allele of rs4979462 enhances TNFSF15 expression by binding NF-1.

Authors:  Yuki Hitomi; Minae Kawashima; Yoshihiro Aiba; Nao Nishida; Mika Matsuhashi; Hitoshi Okazaki; Minoru Nakamura; Katsushi Tokunaga
Journal:  Hum Genet       Date:  2015-04-22       Impact factor: 4.132

8.  Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.

Authors:  William V Perks; Ravinder K Singh; Gareth W Jones; Jason P Twohig; Anwen S Williams; Ian R Humphreys; Philip R Taylor; Simon A Jones; Eddie C Y Wang
Journal:  Am J Pathol       Date:  2016-09-21       Impact factor: 4.307

Review 9.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  Clinical targeting of the TNF and TNFR superfamilies.

Authors:  Michael Croft; Chris A Benedict; Carl F Ware
Journal:  Nat Rev Drug Discov       Date:  2013-01-21       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.